Protocol CCTL019B2206: A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial

Principal Investigator

Brandon Hayes-Lattin

Study Purpose

To collect white blood cells called T-cells through a process called leukapheresis to potentially be used in an experimental approach for treatment of your cancer in a separate treatment research study.

Medical Condition(s)

Multiple cancer disease groups will be studied using this protocol. As of right now, there are protocols for further treatment studies for leukemia, lymphoma, and myeloma.

Eligibility Criteria

Eligibility inclusion criteria:
1. Participant at least 2 years old
2. A CD19 expressing malignancy type of cancer
3. Other inclusion criteria apply

Eligibility exclusion criteria:
1. Pregnant or nursing women
2. Hepatitis B, active Hepatitis C, or any uncontrolled infection at screening
3. HIV+ at screening
4. Presence of grade 2-4 GVHD at screening
5. Other exclusion criteria apply

Age Range

3 - 100

Healthy Volunteers Needed


Duration of Participation

Patients will be followed by phone call every 3 months for 12 months following leukapheresis

Minors Included



Clinical Trials Information Line: Phone 503-494-1080 or


Novartis Pharmaceuticals

Recruitment End


Compensation Provided


Go Back